^
Association details:
| Biomarker: | KRAS G13D |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | SHR-A1307 (EGFR-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies
Excerpt:
SHR-A1307 demonstrated strong and sustained antitumor activities in EGFR-positive tumors harboring different oncogenic mutations on EGFR, KRAS, or PIK3CA...In colorectal cancer and HNSCC cells harboring EGFR downstream mutations in RAS/MAPK or PI3K pathways, SHR-A1307 also exhibited effective cell killing with IC50 values of 8.1 and 17.2 nmol/L in Lovo (KRASG13D) and Detroit562 (PIK3CAH1047R), respectively...
DOI:
10.1158/1535-7163.MCT-18-0854
